拜耳确认:肺动脉高压特效药物万他维并未撤出中国

2015-12-19 刘深 生命时报

<!--ewebeditor:page title=""--> 近日,一则关于肺动脉高压治疗药物万他维,在中国的相关慈善援助项目即将结束,万他维将逐步退出中国市场的消息引发各方关注(<a href="http://www.medsci.cn/article/show_article.asp?id=4861605e4e8" target="_blank">肺动脉高压特效药物万他维可能会退出中国市场,患者面临断药危机</a>)。舆论普遍担忧,万他维放弃中国市场,国内相关患者将面临断药,甚至在危急重症时会有性命之忧。<br> <br> 近日,记者从拜耳处获悉:<span style="font-weight: bold;">万他维还将继续向中国患者提供。</span><br> <br> 拜耳表示,对患者援助项目中已入组患者的援助按原计划继续进行,直到该患者援助周期结束,拜耳正在寻找方案使该产品能够顺畅的供应。<br> <br> <img data-s="300,640" data-type="jpeg" src="https://img.medsci.cn/webedito

近日,一则关于肺动脉高压治疗药物万他维,在中国的相关慈善援助项目即将结束,万他维将逐步退出中国市场的消息引发各方关注(肺动脉高压特效药物万他维可能会退出中国市场,患者面临断药危机)。舆论普遍担忧,万他维放弃中国市场,国内相关患者将面临断药,甚至在危急重症时会有性命之忧。

近日,记者从拜耳处获悉:万他维还将继续向中国患者提供。

拜耳表示,对患者援助项目中已入组患者的援助按原计划继续进行,直到该患者援助周期结束,拜耳正在寻找方案使该产品能够顺畅的供应。



记者了解到,拜耳之前曾告知中国肺动脉高压患者组织“爱稀客”将得到公司总部的相关回复。 “爱稀客”相关负责人李融告诉记者,已于12月19日凌晨3点多收到来自拜耳全球的回复,并称正在征求医生、患者意见等,随后将统一回应此事。

已研究肺动脉高压19年的中国医学科学院阜外医院心内科副主任、教育部***特聘教授荆志成对记者表示:“听到这个消息,我非常高兴!这表明拜耳作为一家国际药企,勇于承担了社会责任。”

他说,万他维是目前国内唯一可以吸入治疗肺动脉高压的药物,在抢救危急重症患者时,具有起效快、副作用小的优势。

记者在中华慈善总会万他维患者援助项目官方网站上看到,该项目于2008年5月中华慈善总会与拜耳医药保健有限公司共同设立,旨在帮助中国肺动脉高压患者获得万他维的治疗,延长生存,提高患者的生活质量。

截止2014年12月底,累计援助患者849人。该项目在64家医院中已经有94名项目注册医生。在全国省、市设立26个发药点。

据悉,项目自2008年5月正式启动至今,已为超过一千名中国患者提供药品,该项目现有患者近100名。(根据中华慈善总会给出的确切数据,截止到11月底,在组患者人数是92人)。

万他维主要用于罕见病特发性肺动脉高压的诊治,作为一种专利药品研发成本巨大。目前,万他维国内售价较高,尚未纳入医保,企业成本压力巨大,患者经济负担沉重。很多医学专家、患者均呼吁,政府应尽快将肺动脉高压纳入医保。

科普链接:肺动脉高压,被你忽视的疾病

很多人对高血压很熟悉,却可能从来没听说过“肺动脉高压”。以前,肺动脉高压被称为“心脑血管领域的癌症”,“一确诊就活不过5年”的说法广为流传。

事实上,除了作为罕见病被媒体报道的特发性肺动脉高压之外,该病已十分常见,但治疗的突破性进展也很多,亟需引起政府和百姓的关注。

为此,《生命时报》专访中国医学科学院阜外医院心内科副主任,教育部***特聘教授荆志成、北京医院心内科副主任刘德平教授,为你详细介绍。

受访专家:
中国医学科学院阜外医院心内科副主任,教育部***特聘教授 荆志成

北京医院心内科副主任 刘德平

治疗突破性进展多北京医院心内科副主任刘德平说,本质上看,肺动脉高压是高血压的一种,指的是因各种原因所引起的肺动脉压力持久性增高,且高出正常最高值。荆志成解释道:

人活着离不开呼吸,每一次呼吸时,血流从右心室射入肺动脉,进入肺脏,通过肺交换将二氧化碳排出体外,将吸入的氧气通过肺静脉运回左心室。

一旦我们的肺动脉堵住了,不少血管就会不通畅,其他通畅的血管就要承载更多的血流量,进而造成肺血管阻力增加,导致右心压力增加,出现“肺动脉高压”,它会严重影响心脏功能。

荆志成告诉《生命时报》记者,准确地说,肺动脉高压是一种临床征象,导致它的原因有几百种,先心病,肺栓塞,肝硬化门脉高压,溶血性贫血,结缔组织疾病如干燥综合征、系统性红斑狼疮、血管炎等都会引起肺动脉高压。

一般来说,世界卫生组织将肺高血压分为分为五大类,所有患者加起来有数百万人,数量十分庞大,很多患者没有得到早期诊断和规范治疗,急需引起政府、医护工作者,以及老百姓的关注和重视。

具体来看,五大类肺高血压分别是指:

第一大类是肺动脉高压,既包括特发性和遗传性肺动脉高压,属于罕见病的一种,我国每年新增此类患者约6500例,目前发病人数已累计五六万人。

也包括比较常见的原因如先心病相关的肺动脉高压,先心病得不到及时治疗易发展为肺动脉高压,肺动脉高压的严重程度又会对先心病患儿的预后产生重要影响;另外我国常见的肺动脉高压的危险因素还有血吸虫病、艾滋病毒感染等。

第二大类是左心疾病引起的肺动脉高血压,如瓣膜疾病、左心收缩功能不全等;

第三大类是呼吸系统疾病引起的肺动脉高血压,如老慢支、慢阻肺、睡眠呼吸暂停综合征等,;

第四大类是慢性血栓栓塞性疾病引起的肺高血压,如肺栓塞、静脉血栓等疾病;

第五大类是混合性肺动脉高压,都是原因不明确的,需要进一步研究。荆志成说,其中第二大类和第三大类的患者加起来就有500万人左右。

有人将肺动脉高压称之为“心脑血管领域的癌症”。在肺动脉高压病友和家属圈,也流传着“一确诊就活不过5年”的说法。在荆志成看来,活不过5年的说法过于绝对。

以中国医学科学院阜外医院为例,2007年,荆志成领导的一项研究显示,该中心确诊后肺动脉高压患者的5年生存率为19%,三年生存率为30%多。但现在8年过去了,目前的最新数据显示,经过规范治疗的5年生存率高达80%,活过10年的患者不在少数。

“肺动脉高压之所以比较影响寿命,主因是心衰。但在肺动脉高压治疗领域,近些年的进展非常迅速。肺动脉高压更像是介于癌症和高血压、糖尿病等慢性病之间的一种疾病,但具有突破性的治疗进展远高于糖尿病、高血压领域。”荆志成表示,治疗的第一步是找准病因,病因不同,治疗方法也不同。

目前,除了吸氧、服用钙拮抗剂等传统治疗外,临床上治疗肺动脉高压的靶向新药很多,主要有内皮素受体拮抗剂,如波生坦和安立生坦;磷酸二酯酶抑制剂(西地那非),老百姓常说的“伟哥”是其中一种。我们研究发现,价格相对便宜的盐酸伐地那非也安全有效。

此外,还有曲前列素、贝前列素、万他维等。前者美国已有口服,我国则仍是皮下或者静脉注射用药。除了药物治疗外,还有手术治疗,如阜外医院荆志成教授团队可以完全通过手术剥掉增生内膜治疗慢性血栓栓塞性疾病,达到几乎治愈的效果。目前,国际上还有很多疗效较好的新药尚未进入中国,正在研究的新药也非常多。

荆志成告诉记者,他一直有两个期待。

一是患者按规范治疗,不轻易放弃。门诊中,常有患者因病情暂时稳定、经济压力太大、求助中医甚至保健品等原因中途放弃治疗,导致不少人再回到医院时病情已严重恶化,剩余寿命大大缩短。他期待患者,一定要坚持治疗,每隔3~6个月定期复查,因为该病变化十分迅速;

二是期待国家尽早将肺动脉高压纳入医保,调整国外新药审批政策,让中国患者尽早享受到国外的最新药物和疗法。肺动脉高压人群庞大,他们经济压力巨大,以波生坦为例,每月花费至少3900元,这对普通家庭来说无疑是沉重负担。

“我经常跟患者讲,肺动脉高压的新疗法日新月异,今天的治疗虽然不能彻底根治你的疾病,但能让你有机会活到明年,等待更大的治疗甚至治愈希望的出现。”荆志成说,患者和家属一定要有战胜疾病、坚持规范治疗的信心。政府对肺动脉高压也越来越重视,未来完全是可以期待的。

发病各年龄段都有 “在很长一段时间里,肺动脉高压被认为只在20~40岁中青年人群中高发。上世纪八九十年代,欧洲相关调查发现,该病的平均发病年龄为36岁,但近几年来自美国、法国等多国数据显示,平均发病年龄为50多岁。

其原因并不是患者年龄增加,而是很多老年人也被诊断出来了,”荆志成告诉《生命时报》记者。他研究肺动脉高压已19年,是国内该领域的权威专家。在中国医学科学院阜外医院就诊的病人中,除中青年外,也有数百名儿童和数百名老年人。

很多老百姓也不了解这个病,导致不少人一确诊便已到晚期,严重影响寿命。总体上看,不同年龄段,病因略有差异,如青少年儿童多因先心病、代谢疾病;老年人群多因呼吸系统疾病、心衰等;中青年人群则多与内分泌、血管炎、代谢疾病、减肥药等有关。

减肥药主要是芬氟拉明,它会损伤肺血管。2008年,我国已禁止减肥药芬氟拉明及其原料的生产,但仍有不法商贩为了利益违规操作。

早诊高危人群半年查一次“早期诊断对肺动脉高压患者的预后至关重要,”荆志成说,肺动脉高压的常见症状是活动时气短(比如爬楼就喘)、下肢水肿、咳血、晕厥等,这与不少疾病类似,加上导致肺动脉高压的原因很多,需要医生了解心脑血管疾病、呼吸系统疾病、结缔组织疾病、代谢疾病、肝病等多领域疾病,才能做出准确判断。

临床上,不少医生缺乏诊断意识,对引起肺动脉高压的病因不清楚,从而对肺动脉高压的诊断鉴别不太熟悉,加上很多医生右心导管技术、精准超声心动图技术不过关,导致临床上肺动脉高压误诊时有发生。

荆志成强调,明确诊断是否是肺动脉高压需要做一系列检查,普通老百姓只需牢记两大关键,:

第一,高危人群不管是哪个年龄段的,应每隔半年到大医院心脏或心内科做超声检查,一旦出现活动后气短,应该立即去心血管专科就诊,如果发现有右心房右心室的扩大,三尖瓣反流压差增加,需提高警惕。高危人群指的是有先心病、结缔组织病、门脉高压、呼吸系统疾病、艾滋病病毒感染或家族中有肺动脉高压病史的人、服用过减肥药者等群体;

第二,右心导管技术是确诊肺动脉高压的标准,它还能诊断具体是哪种血流动力学类型。

生活四项注意要牢记如果已确诊为肺动脉高压,生活中应注意以下几点:

避免剧烈运动。一旦确诊为肺动脉高压,哪怕病情好转,也不宜重体力劳动,不要进行爬山、游泳、下海、划船、快跑、打篮球等剧烈的体育运动。建议选择平地散步等较轻松的活动。同时,还应避免在餐后、气温过高和过低的环境中运动。

别让感染找上你。感冒等呼吸道感染带来的危险可能是致命的,外出时应注意保暖,少去人群密集的地方,避免感冒。刘德平说,患者平时应规律生活、按时作息,均衡饮食,避免情绪大喜大悲。

少去海拔高的地方。尽量不要到氧气稀薄的地方(即海拔高度超过2000公尺),缺氧会使您的肺血管收缩,加重肺动脉高压。

注意避孕。刘德平说,不少肺动脉高压患者是女性,育龄期妇女应注意避孕,因为怀孕和生育会加重病情。

刘德平说,肺动脉高压本身可能较难预防,但我们可以积极预防易引起肺动脉高压的疾病,如代谢性疾病、呼吸系统疾病等。生活中,大家应养成健康的生活方式,积极锻炼,增强心肺功能。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1925140, encodeId=5ede192514027, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 14:26:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64993, encodeId=851a649938d, content=太感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b101689215, createdName=1de53497m25(暂无匿称), createdTime=Sat Feb 20 22:34:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900345, encodeId=d49f19003455b, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 18 18:26:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55145, encodeId=f72c551457b, content=非得外国确认…, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55146, encodeId=a36d5514683, content=有点可悲!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55147, encodeId=395f5514e6d, content=唉…, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49996, encodeId=fe9949996ad, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49997, encodeId=b8524999eb9, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49998, encodeId=23924999885, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318442, encodeId=3a141318442e5, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Mon Dec 21 13:26:00 CST 2015, time=2015-12-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1925140, encodeId=5ede192514027, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 14:26:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64993, encodeId=851a649938d, content=太感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b101689215, createdName=1de53497m25(暂无匿称), createdTime=Sat Feb 20 22:34:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900345, encodeId=d49f19003455b, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 18 18:26:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55145, encodeId=f72c551457b, content=非得外国确认…, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55146, encodeId=a36d5514683, content=有点可悲!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55147, encodeId=395f5514e6d, content=唉…, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49996, encodeId=fe9949996ad, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49997, encodeId=b8524999eb9, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49998, encodeId=23924999885, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318442, encodeId=3a141318442e5, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Mon Dec 21 13:26:00 CST 2015, time=2015-12-21, status=1, ipAttribution=)]
    2016-02-20 1de53497m25(暂无匿称)

    太感谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1925140, encodeId=5ede192514027, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 14:26:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64993, encodeId=851a649938d, content=太感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b101689215, createdName=1de53497m25(暂无匿称), createdTime=Sat Feb 20 22:34:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900345, encodeId=d49f19003455b, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 18 18:26:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55145, encodeId=f72c551457b, content=非得外国确认…, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55146, encodeId=a36d5514683, content=有点可悲!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55147, encodeId=395f5514e6d, content=唉…, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49996, encodeId=fe9949996ad, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49997, encodeId=b8524999eb9, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49998, encodeId=23924999885, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318442, encodeId=3a141318442e5, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Mon Dec 21 13:26:00 CST 2015, time=2015-12-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1925140, encodeId=5ede192514027, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 14:26:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64993, encodeId=851a649938d, content=太感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b101689215, createdName=1de53497m25(暂无匿称), createdTime=Sat Feb 20 22:34:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900345, encodeId=d49f19003455b, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 18 18:26:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55145, encodeId=f72c551457b, content=非得外国确认…, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55146, encodeId=a36d5514683, content=有点可悲!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55147, encodeId=395f5514e6d, content=唉…, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49996, encodeId=fe9949996ad, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49997, encodeId=b8524999eb9, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49998, encodeId=23924999885, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318442, encodeId=3a141318442e5, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Mon Dec 21 13:26:00 CST 2015, time=2015-12-21, status=1, ipAttribution=)]
    2016-01-09 medsic

    非得外国确认…

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1925140, encodeId=5ede192514027, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 14:26:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64993, encodeId=851a649938d, content=太感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b101689215, createdName=1de53497m25(暂无匿称), createdTime=Sat Feb 20 22:34:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900345, encodeId=d49f19003455b, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 18 18:26:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55145, encodeId=f72c551457b, content=非得外国确认…, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55146, encodeId=a36d5514683, content=有点可悲!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55147, encodeId=395f5514e6d, content=唉…, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49996, encodeId=fe9949996ad, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49997, encodeId=b8524999eb9, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49998, encodeId=23924999885, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318442, encodeId=3a141318442e5, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Mon Dec 21 13:26:00 CST 2015, time=2015-12-21, status=1, ipAttribution=)]
    2016-01-09 medsic

    有点可悲!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1925140, encodeId=5ede192514027, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 14:26:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64993, encodeId=851a649938d, content=太感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b101689215, createdName=1de53497m25(暂无匿称), createdTime=Sat Feb 20 22:34:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900345, encodeId=d49f19003455b, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 18 18:26:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55145, encodeId=f72c551457b, content=非得外国确认…, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55146, encodeId=a36d5514683, content=有点可悲!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55147, encodeId=395f5514e6d, content=唉…, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49996, encodeId=fe9949996ad, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49997, encodeId=b8524999eb9, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49998, encodeId=23924999885, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318442, encodeId=3a141318442e5, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Mon Dec 21 13:26:00 CST 2015, time=2015-12-21, status=1, ipAttribution=)]
    2016-01-09 medsic

    唉…

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1925140, encodeId=5ede192514027, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 14:26:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64993, encodeId=851a649938d, content=太感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b101689215, createdName=1de53497m25(暂无匿称), createdTime=Sat Feb 20 22:34:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900345, encodeId=d49f19003455b, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 18 18:26:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55145, encodeId=f72c551457b, content=非得外国确认…, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55146, encodeId=a36d5514683, content=有点可悲!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55147, encodeId=395f5514e6d, content=唉…, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49996, encodeId=fe9949996ad, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49997, encodeId=b8524999eb9, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49998, encodeId=23924999885, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318442, encodeId=3a141318442e5, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Mon Dec 21 13:26:00 CST 2015, time=2015-12-21, status=1, ipAttribution=)]
    2015-12-28 wzf990214

    有意思

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1925140, encodeId=5ede192514027, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 14:26:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64993, encodeId=851a649938d, content=太感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b101689215, createdName=1de53497m25(暂无匿称), createdTime=Sat Feb 20 22:34:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900345, encodeId=d49f19003455b, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 18 18:26:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55145, encodeId=f72c551457b, content=非得外国确认…, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55146, encodeId=a36d5514683, content=有点可悲!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55147, encodeId=395f5514e6d, content=唉…, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49996, encodeId=fe9949996ad, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49997, encodeId=b8524999eb9, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49998, encodeId=23924999885, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318442, encodeId=3a141318442e5, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Mon Dec 21 13:26:00 CST 2015, time=2015-12-21, status=1, ipAttribution=)]
    2015-12-28 wzf990214

    不错哦

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1925140, encodeId=5ede192514027, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 14:26:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64993, encodeId=851a649938d, content=太感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b101689215, createdName=1de53497m25(暂无匿称), createdTime=Sat Feb 20 22:34:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900345, encodeId=d49f19003455b, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 18 18:26:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55145, encodeId=f72c551457b, content=非得外国确认…, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55146, encodeId=a36d5514683, content=有点可悲!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55147, encodeId=395f5514e6d, content=唉…, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49996, encodeId=fe9949996ad, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49997, encodeId=b8524999eb9, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49998, encodeId=23924999885, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318442, encodeId=3a141318442e5, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Mon Dec 21 13:26:00 CST 2015, time=2015-12-21, status=1, ipAttribution=)]
    2015-12-28 wzf990214

    赞一个

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1925140, encodeId=5ede192514027, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Feb 11 14:26:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64993, encodeId=851a649938d, content=太感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b101689215, createdName=1de53497m25(暂无匿称), createdTime=Sat Feb 20 22:34:00 CST 2016, time=2016-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900345, encodeId=d49f19003455b, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Jul 18 18:26:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55145, encodeId=f72c551457b, content=非得外国确认…, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55146, encodeId=a36d5514683, content=有点可悲!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55147, encodeId=395f5514e6d, content=唉…, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:14:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49996, encodeId=fe9949996ad, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49997, encodeId=b8524999eb9, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49998, encodeId=23924999885, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:49:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318442, encodeId=3a141318442e5, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Mon Dec 21 13:26:00 CST 2015, time=2015-12-21, status=1, ipAttribution=)]
    2015-12-21 ying_wu

相关资讯

J Heart Lung Transplant:慢性血栓性肺动脉高压患者改善右室功能可选择球囊肺动脉成形术

背景:慢性血栓性肺动脉高压(CTEPH)致右心室(RV)适应性改变,常致RV衰竭及死亡。球囊肺动脉成形术(BPA)是肺动脉内膜切除术禁忌及肺动脉内膜切除术后残余肺动脉高压患者的一种治疗方法。研究者假设CTEPH患者BPA后RV重塑逆转机改善RV功能。方法:26个CTEPH患者(59 ± 12岁,11个男性患者),在进行前后4±2 BPA进行超声心动图,心肺运动实验,血液样本及右心导管的检查。根据当

Circulation:两机构联合推出儿科肺动脉高压临床治疗指南

2015年11月3日,美国心脏学会(The American Heart Association)与美国胸科学会( American Thoracic Society)在Circulation杂志上联合发布了第一版的评估和治疗儿科肺动脉高压( pulmonary hypertension , PH)的临床实践指南。两机构联合推出这份实践指南的目的基于在临床上,新生儿、幼儿的PH发病原因与治疗方式均

肺动脉高压特效药物万他维可能会退出中国市场,患者面临断药危机

2015年12月10日,一封由1400余名患者、医生、人大代表、病友组织、社会人士联名签署的公开信,以电子邮件的形式被发送到拜耳医药保健有限公司总部,希望其留下即将退出中国的肺动脉高压药“万他维”。 这一切源自半年前一封信。6月29日,中华慈善总会万他维患者援助项目办公室突然发出通知,终止万他维患者援助项目。通知中说,“由于捐赠方拜耳公司全球策略调整,万他维自2015年起将逐步退出中国市场”

ESC 2015:肺动脉高压指南亮点

1,新的治疗流程是新版指南最大亮点,并给出简明表格提示应当何时使用新近批准上市的药物。治疗策略基于患者的风险评估。2,指南基于近期研究证据对序贯和初始联合治疗做了推荐,并首次推荐“早期考虑行肺移植治疗”。3,针对CTEPH(慢性血栓栓塞性肺高压)也推荐了新的治疗流程,包括外科、药物和介入治疗。4,指南基于新证据更新了肺高压的临床和血流动力学分型,对儿科情况也进行了分类,并将肺血管抵抗(pulmon

NEJM:安贝生坦和他达拉非初始联合治疗肺动脉高压已见成效

使用安贝生坦和他达拉非初始联合治疗肺动脉高压患者长期预后的的效果数据少之又少。在这项事件驱动的、双盲研究中,研究人员随机以2:1:1的比例分配世界卫生组织功能II级或III症状的肺动脉高压且以前没有接受过治疗的患者接受初步联合治疗,即10毫克安贝生坦加40毫克他达拉非(联合治疗组),或10毫克安贝生坦+安慰剂(安贝生坦单药治疗组),或40毫克他达拉非加安慰剂(他达那非单药治疗组),全部给予每日一次

荆志成教授:从肺动脉高压研究史,探ESC 2015新指南新意

中国医学科学院阜外医院荆志成教授 ESC上版肺动脉高压诊疗指南发布于2009年,今年ESC年会期间将发布新指南。荆志成教授指出,近20余年,学界在肺动脉高压发病机制、遗传学、诊断分类及治疗、新药研发等方面均取得显著进展,指南更新势在必行。2014年,相关专家向ESC提出更新指南,更新点包括流行病学数据、遗传学发现(2013年新发现基因突变引起平滑肌细胞钾通道开放障碍导致肺动脉高压)、发病机制